A Phase 2a Multicentre, Randomized, Open-Label, Two-Part Adaptive Design Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A, an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody in Antiretroviral-naive HIV-1-Infected Adults

Date Added
June 15th, 2021
PRO Number
Pro00110807
Researcher
Eric Meissner

List of Studies


Keywords
HIV / AIDS
Summary

The purpose of this study is to evaluate the safety and efficacy of an investigational drug in adults with a clinical diagnosis of Human Immunodeficiency Virus (HIV). This study aims to determine if receipt of a one-time infusion or sub-cutaneous (under the skin) administration of the study drug results in a longer lasting response against HIV. The study drug will be given in addition to the standard of care treatment. The study of this investigational drug represents a novel approach to the treatment of this condition. Participation in the study will involve a minimum of 10 visits to the study clinic over a period of 1 month, followed by initiation of standard of care treatment.

Institution
MUSC
Recruitment Contact
Lisa Martin
843-876-5699
martinl@musc.edu

Elucidating Mechanisms of Treatment Relapse for Interferon-Free HCV Therapy

Date Added
August 18th, 2015
PRO Number
Pro00046669
Researcher
Eric Meissner

List of Studies


Keywords
Digestive System, HIV / AIDS, Immune System, Infectious Diseases, Liver
Summary

Treatment of chronic hepatitis C virus (HCV) infection is now possible with all oral medications. While most patients achieve a sustained virologic response (SVR) after treatment, synonymous with cure, some patients relapse after treatment for reasons that are unclear. The goal of this research is to understand how a person's immune system changes during treatment of HCV infection with all oral therapy, and how these changes might impact the chances of relapse after treatment. To address these questions, blood and clinical information will be collected from study participants over the course of receiving standard of care treatment for HCV infection. This blood and clinical information will be used to conduct laboratory research focused on the immune system.

Institution
MUSC
Recruitment Contact
Lisa Martin
843-876-5699
martinl@musc.edu



-- OR --